Precision BioSciences (DTIL) announced that the U.S. Food and Drug Administration or FDA has cleared the Investigational New Drug application ...

Hepatitis B virus infection remains one of the leading causes of liver disease, including cirrhosis and hepatocellular carcinoma.

Scientists discovered a way to block hepatitis B infection using an anticancer drug, offering hope for new treatments.

The US joins Moldova, Hong Kong, and New Zealand as countries to greenlight the company's Phase I trial of PBGENE-HBV.

However, I was fascinated to discover that viruses like hepatitis B hijack epigenetic mechanisms, even using human DNA-packaging proteins to regulate their activity." Not long after, Dr. Prescott ...

However, I was fascinated to discover that viruses like hepatitis B hijack epigenetic mechanisms, even using human DNA-packaging proteins to regulate their activity.” Not long after, study first ...

ELIMINATE-B Phase 1 dose finding study for chronic Hepatitis B executing on schedule with completion of first dose administration for cohort 1 (n=3 patients) PBGENE-HBV, the first LNP gene editing ...

Precision aims to define the optimal dose and number of administrations for the elimination of covalently closed circular DNA (cccDNA), in addition to the inactivation of integrated HBV DNA.

Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...

Atomic force microscopy images show hepatitis B DNA in its natural state (left) and a zoomed-in look at how it wraps around human histones during an infection (right). The research team determined ...